Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Omic Technologies to Track Resistance to Palbociclib in Metastatic Breast Cancer (OMERIC): A Cohort Study

NCT04653740 is registered in ClinicalTrials.gov with Centre Oscar Lambret as lead sponsor.

NCT NCT04653740
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04653740 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Omic Technologies to Track Resistance to Palbociclib in Metastatic Breast Cancer (OMERIC): A Cohort Study
Lead sponsor
Centre Oscar Lambret
Phase
Not applicable
Overall status
Active, not recruiting
Start date
September 8, 2020
Completion date
November 30, 2027
Enrollment
25 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced breast cancer